Skip to main content

Health innovation delivered.

Newmarket Strategy is a specialist market access consultancy. We provide strategic advice and technical support to help healthcare and life sciences organisations bring innovations to patients faster.

Part 1: How to influence national systems to help mitigate MFN headwinds
May 12th, 2026
By
Robert Kettell
Part 2: Asset level commercial strategies alongside national level system change
June 4th, 2026
By
Robert Kettell

Who we are

Specialists in market access, we provide strategic advice & technical support to the healthcare and life sciences sector.

+95%

Of clients choose our senior partner expertise

81

Top rated Client Advocacy Score

78%

Rank Newmarket Strategy as their number 1 consultancy

What we do

Pillars of our expertise

Newmarket Strategy has industry-leading expertise supporting market access strategy through policy, reimbursement and evidence synthesis.

0

Value & Access

Empowering organisations to set commercial strategy, demonstrate value and secure reimbursement.

0

Global Health Policy & Government Affairs

Helping organisations navigate complex political landscapes, influence decision makers, and shape health policy.

0

Health Economics & Evidence Synthesis

Harnessing robust data and economic modelling to build a compelling evidence base and drive market uptake.

Why us

Senior counsel.
Deep specialism.
Candid advice.

Clients choose Newmarket Strategy for the experience of its people and the clarity of its counsel.

The team brings unrivalled experience from industry, government, health systems, reimbursement and HTA bodies, analytical sciences and clinical practice.

Experts by experience

Strategic advice shaped by partners who have held senior executive roles across the health and life sciences industry.

Connected expertise

Policy, access, evidence and strategy brought together around the same problem.

Clear counsel

Direct guidance on what matters, what works and where to focus.

Our team

Actionable advice from leaders who understand how to commercialise great science

Newmarket Strategy brings together market access specialists, healthcare policy experts and analytical scientists

Newmarket Strategy brings together market access specialists, healthcare policy experts and analytical scientists

Edward Jones
Chief Executive Officer
Team
A leading UK health policy expert, Ed has advised at the highest levels within government, the NHS and industry.
Edward Jones
Chief Executive Officer
Emma Allen
Chief Operating Officer
Team
Emma Allen is an experienced professional in the Scientific Community, having previously worked in industry as a scientist with both Pfizer and GSK before transitioning to a finance role.
Emma Allen
Chief Operating Officer
Berkeley Greenwood
Senior Partner
Team
Berkeley has nearly three decades of experience in advising organisations at national and international level.
Berkeley Greenwood
Senior Partner
James O'Shaughnessy
Senior Partner
Team
One of the UK's leading policy advisors. Operated at the highest levels of government as a Minister at the Department for Health & Social Care, Director of the No.10 Policy Unit, and advisor to DHSC Ministers during COVID-19.
James O'Shaughnessy
Senior Partner
Blake Dark
Senior Partner
Team
Blake is a globally connected commercial expert in pharma and health technologies.
Blake Dark
Senior Partner
Bill Morgan
Senior Partner
Team
Has advised Prime Ministers, health ministers and leading life sciences businesses for over two decades. Before joining Newmarket, served as No.10's Special Adviser for Health, Social Care and Life Sciences.
Bill Morgan
Senior Partner
Neil Hawkins
Senior Partner
Team
Vice Chair, NICE Diagnostics Committee. Professor of Health Technology Assessment at the University of Glasgow. 20+ years in HTA leadership roles across multiple therapy areas and global markets.
Neil Hawkins
Senior Partner
David Scott
Senior Partner
Team
Specialist in real-world evidence, systematic reviews and evidence synthesis for HTA across multiple therapy areas.
David Scott
Senior Partner
Edit Remák
Senior Partner
Team
Founder of Visible Analytics with 20+ years in health economic modelling. Led the VA team through its acquisition by Newmarket Strategy, combining deep HEOR expertise with strategic market access insight across oncology, rare disease and multiple regions.
Edit Remák
Senior Partner
Noémi Muszbek
Senior Partner
Team
Co-founder of Visible Analytics. Senior health economist with 26 years' experience across pharma, payer and consultancy, working across many indications in global HTA markets.
Noémi Muszbek
Senior Partner

Where we are

Global outlook, rooted in local market knowledge

Newmarket Strategy supports clients across the UK, Europe and beyond.


We combine local health system knowledge with wider policy, access and commercial experience.

Case study

Building a clearer evidence & access strategy

Testimonials

Testimonials

1
/
9

“The quality of insights in terms of understanding the government and health system thinking: it’s unmatched due to the quality of the senior team.”

Senior Partner
Life sciences organisation

"Their expertise in strategy, candour, and flexibility has been invaluable to our work."

Strategy Client
Pharmaceutical company

“They are more connected across my policy world than any other agency out there.”

Policy & Public Affairs Client
Medical technology company

“They have advisors who have worked at the highest levels of health systems and government. That credibility is key.”

Partner
Market access pharmaceutical company

"The team I engage with has almost recreated a health system team within a consultancy. That's really appealing because it makes the advice we get feel like an inside view."

Health System Client
Pharmaceutical company

Our insights

Dive into our latest insights & thinking

Practical thinking on the access, policy, commercial and health system issues shaping healthcare and life sciences.

Pharma
5
min read

Part 2: Asset level commercial strategies alongside national level system change

Innovative commercial strategies to achieve an optimal net price have never been more critical – and achieving them will demand a higher appetite for risk from all parties.

4/6/26
Pharma
5
min read

Part 2: Asset level commercial strategies alongside national level system change

4/6/26
Pharma
4
min read

Part 1: How to influence national systems to help mitigate MFN headwinds

12/5/26
Announcements
3
min read

NHS pharmaceuticals negotiator to join Newmarket Strategy

3/12/25

Events

See where our team will be speaking, attending or hosting next

13
-
14 Oct
Barcelona
Scope Conference Europe 2026

This premier clinical operations event gathers over 700 senior executives to explore clinical trial innovation, AI implementation, and site engagement.

View event
23
-
27 Oct
Madrid
ESMO Congress 2026

Newmarket Strategy will be attending ESMO Congress 2026 to connect with clients, partners and industry colleagues working across evidence, analytics, HTA and market access.

View event
8
-
11 Nov
Vienna
ISPOR Europe 2026

ISPOR Europe 2026 is the leading HEOR (Health Economics and Outcomes Research) conference taking place November 8–11 at the Austria Center Vienna.

View event
2
-
3 Mar
Amsterdam
World Congress EPA 2027

Join us at World EPA 2027 as we showcase how strategic evidence planning, expert analytics and communication excellence empower lifesciences companies to stay ahead in a rapidly evolving HTA environment. Visit our booth and connect with our team in Amsterdam.

View event

FAQ

Your questions answered

Newmarket Strategy helps healthcare, life sciences and health tech organisations make better decisions across policy, market access, reimbursement, evidence and commercial strategy.

We bring together senior experience from industry, government, the NHS, reimbursement bodies and clinical practice. Our teams combine expertise in global health policy, health economics and evidence synthesis, and value and access, giving clients connected advice grounded in how healthcare decisions are made.

Yes. We help healthcare and life sciences organisations demonstrate the value of their innovations and navigate routes to access and reimbursement. By bringing together commercial strategy, policy insight and robust evidence, we help clients plan how to bring their products to market and support their adoption.